Looks like you’re on the UK site. Choose another location to see content specific to your location
Eisai extends research partnership with Charles River Laboratories
Eisai has announced that its two-year integrated drug discovery partnership with Charles River Laboratories is to be extended for an additional year.
The collaboration is focused on the discovery of novel treatments for tropical and neurological diseases, with activities taking place at Eisai's 14.5-acre European Knowledge Centre in Hatfield.
The initial research was funded by the Global Health Innovative Technology Fund, with researchers now set to work closely with the Medicines for Malaria Venture on the discovery of new antimalarial compounds that aim to fight drug-resistant strains of the disease.
Malaria is an important target due to its status as one of the three most prominent infectious diseases in the world, as well as the fact that malaria parasites are believed to be developing drug resistance, creating an urgent need for alternative treatments.
Gary Hendler, chairman and chief executive officer for Eisai in Europe, the Middle East and Africa, said: "Charles River has a proven track record of success in drug discovery and innovative chemistry capabilities. This partnership supports Eisai's commitment to investigating and developing innovative treatments, in line with our human health care mission."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard